Dr Edwin Wong is a Consultant Nephrologist at the National Renal Complement Therapeutics Centre and the Freeman Hospital’s Renal Services Centre. He is also an associate clinical lecturer at Newcastle University.
Dr Wong leads nationally on C3 glomerulopathy and is responsible for the implementation of the clinical commissioning policy for the use of eculizumab in recurrent C3G in England. He is a member of the consultant team that delivers the National aHUS Service.
Dr Wong’s academic renal training took place in Newcastle where he completed my Medical Research Council funded Clinical Research Training Fellowship and was awarded a PhD in June 2016.
Research
Dr Wong undertook research in the disease areas membranoproliferative glomerulonephritis (MPGN), C3 glomerulopathy (C3G) and atypical haemolytic uraemic syndrome (aHUS) through laboratory and clinical research methods. He was awarded the Renal Association Raine Award in 2016.
He is an investigator in NIHR portfolio studies, including chief investigator in the UK for two commercial studies in C3G.
His team in Newcastle recently achieved global first patient first visit and global first patient first treatment in both of these studies. In addition, Dr Wong is currently principal investigator on studies into aHUS and IgA nephropathy.
Other roles
- Chair of the MPGN/C3G rare disease group since 2018
- Speciality group lead for renal medicine for North East and North Cumbria since 2019
- Elected member of the Renal Association Council since 2020
